12:00 PM ET
Scholar Rock introduces ISEMBYLD, the first and only FDA-approved muscle-targeted treatment for SMA. This presentation will explore the persistent unmet need in SMA, the importance of directly targeting muscle, and how ISEMBYLD works alongside SMN2-targeted treatment to improve motor function. Attendees will also learn about the clinical evidence, treatment experience, and resources available through Scholar Rock Supports.